Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: Report of a case

Shelly S. Lo, Georgios I. Papachristou, Sydney D. Finkelstein, William P. Conroy, Wolfgang H. Schraut, Ramesk K Ramanathan

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.

Original languageEnglish (US)
Pages (from-to)1316-1319
Number of pages4
JournalDiseases of the Colon and Rectum
Volume48
Issue number6
DOIs
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Gastrointestinal Stromal Tumors
Rectum
Exons
Neoplasms
Microdissection
Neoplasm Micrometastasis
Neoadjuvant Therapy
Disease-Free Survival
Gastrointestinal Tract
Neoplasm Metastasis
Lung
Therapeutics
Imatinib Mesylate

Keywords

  • Gastrointestinal stromal tumor
  • Imatinib
  • Microdissection genotyping
  • Rectal tumor

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum : Report of a case. / Lo, Shelly S.; Papachristou, Georgios I.; Finkelstein, Sydney D.; Conroy, William P.; Schraut, Wolfgang H.; Ramanathan, Ramesk K.

In: Diseases of the Colon and Rectum, Vol. 48, No. 6, 06.2005, p. 1316-1319.

Research output: Contribution to journalArticle

Lo, Shelly S. ; Papachristou, Georgios I. ; Finkelstein, Sydney D. ; Conroy, William P. ; Schraut, Wolfgang H. ; Ramanathan, Ramesk K. / Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum : Report of a case. In: Diseases of the Colon and Rectum. 2005 ; Vol. 48, No. 6. pp. 1316-1319.
@article{f0d6da85dceb4851b1b045bbfea3e2f7,
title = "Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum: Report of a case",
abstract = "Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.",
keywords = "Gastrointestinal stromal tumor, Imatinib, Microdissection genotyping, Rectal tumor",
author = "Lo, {Shelly S.} and Papachristou, {Georgios I.} and Finkelstein, {Sydney D.} and Conroy, {William P.} and Schraut, {Wolfgang H.} and Ramanathan, {Ramesk K}",
year = "2005",
month = "6",
doi = "10.1007/s10350-004-0922-3",
language = "English (US)",
volume = "48",
pages = "1316--1319",
journal = "Diseases of the Colon and Rectum",
issn = "0012-3706",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Neoadjuvant imatinib in gastrointestinal stromal tumor of the rectum

T2 - Report of a case

AU - Lo, Shelly S.

AU - Papachristou, Georgios I.

AU - Finkelstein, Sydney D.

AU - Conroy, William P.

AU - Schraut, Wolfgang H.

AU - Ramanathan, Ramesk K

PY - 2005/6

Y1 - 2005/6

N2 - Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.

AB - Gastrointestinal stromal tumors are rare tumors of the gastrointestinal tract. Gastrointestinal stromal tumors involving the rectum are uncommon. We describe a case of a 43-year-old female with a gastrointestinal stromal tumor of the rectum who declined abdominoperineal resection. Neoadjuvant treatment with imatinib decreased her tumor size, permitting sphincter-sparing transanal excision. She had no evidence of disease for 24 months postoperatively until she recurred with lung metastases. Microdissection genotyping of the recurrent lesion revealed a deletion in exon 11. Further mutational analysis showed that her metastatic lesion was concordant with her primary rectal lesion, suggesting that systemic micrometastasis was previously present at initial diagnosis. Deletion in exon 11 predicts for response with imatinib treatment and is associated with a longer event-free and overall survival. Current studies are underway that may help us optimize the treatment for patients with gastrointestinl stromal tumors.

KW - Gastrointestinal stromal tumor

KW - Imatinib

KW - Microdissection genotyping

KW - Rectal tumor

UR - http://www.scopus.com/inward/record.url?scp=21244447695&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21244447695&partnerID=8YFLogxK

U2 - 10.1007/s10350-004-0922-3

DO - 10.1007/s10350-004-0922-3

M3 - Article

C2 - 15793646

AN - SCOPUS:21244447695

VL - 48

SP - 1316

EP - 1319

JO - Diseases of the Colon and Rectum

JF - Diseases of the Colon and Rectum

SN - 0012-3706

IS - 6

ER -